Article

Efficacy of Adalimumab in Moderate-to-Severe Pediatric Crohn's Disease

Department of Pediatrics, Pediatric Gastroenterology and Liver Unit, University Hospital Umberto I, Sapienza University of Rome, Rome 324-00161, Italy.
The American Journal of Gastroenterology (Impact Factor: 9.21). 07/2009; 104(10):2566-71. DOI: 10.1038/ajg.2009.372
Source: PubMed

ABSTRACT The use of tumor necrosis factor-alpha (TNF-alpha) antagonists has changed the therapeutic strategy for Crohn's disease (CD). Adalimumab (ADA), a fully human anti-TNF-alpha monoclonal antibody, is an effective therapy for patients with CD, both naive patients and those intolerant or refractory to Infliximab (IFX), a chimeric anti-TNF-alpha agent. However, the use of ADA is rarely reported in pediatric CD. We performed an open prospective evaluation of short- and long-term efficacy and safety of ADA in children with moderate-to-severe CD.
A total of 23 pediatric CD patients (9 naive and 14 intolerant or unresponsive to IFX) received ADA subcutaneously as a loading schedule at weeks 0 and 2, and at every other week (eow) during a 48-week maintenance phase. Loading and maintenance doses were 160/80 and 80 mg eow in 13 cases, 120/80 and 80 mg eow in 2, and 80/40 and 40 mg eow in 8 cases. The primary efficacy outcomes were clinical remission and response at different scheduled visits along the maintenance phase. At baseline, 13 patients also received immunomodulators (IMs).
At weeks 2, 4, 12, 24, and 48, remission rates were 36.3, 60.8, 30.5, 50, and 65.2%, respectively, whereas response rates were 87, 88, 70, 86, and 91%, respectively. Four patients at week 24 and 2 at week 48 received IMs; the mean daily corticosteroid dose, disease activity index, C-reactive protein level, and erythrocyte sedimentation rate decreased significantly throughout the trial. No serious adverse events were recorded.
ADA can be an effective and safe biological agent for inducing and maintaining remission in children with moderate-to-severe CD, even in those with previous IFX therapy.

Full-text

Available from: Salvatore Oliva, Mar 30, 2014
1 Follower
 · 
118 Views
  • [Show abstract] [Hide abstract]
    ABSTRACT: A young patient with Crohn's disease is presented in whom pulmonary carcinoid tumor was incidentally found. Bronchoscopy showed an endobronchial lesion and biopsy pathology was consistent with atypical carcinoid. Octeotride scan suggested primary origin of the tumor. Although patients with Crohn's disease have been reported to have increased incidence of intestinal carcinoid, we believe this to be the second case of primary carcinoid pulmonary located in this population.
    02/2013; 2(1):E29-32. DOI:10.3978/j.issn.2218-6751.2012.12.03
  • [Show abstract] [Hide abstract]
    ABSTRACT: The development of biological agents with specific immunological targets has revolutionised the treatment of a wide variety of paediatric diseases where traditional immunosuppressive agents have been partially ineffective or intolerable. The increasing requirement for pharmaceutical companies to undertake paediatric studies has provided impetus for studies of biologics in children. The assessment of biologic agents in children to date has largely relied upon randomised control trials using a withdrawal design, rather than a parallel study design. This approach has been largely used due to ethical concerns including use of placebo treatments in children with active chronic disease, and justified on the basis that treatments have usually already undergone robust assessment in related adult conditions. However, this study design limits the reliability of the data and can confuse the interpretation of safety results. Careful on-going monitoring of safety and efficacy in real-world practice through national and international biologics registries and robust reporting systems is crucial. The most commonly used biologic agents in children target TNF-α, IL-1, IL-6 and CTLA-4. These are most frequently used in paediatric rheumatic diseases. This review will discuss the development and assessment of biologics within paediatric rheumatology with reference to the lessons learned from use in other sub-specialties.
    British Journal of Clinical Pharmacology 04/2014; 79(3). DOI:10.1111/bcp.12406 · 3.69 Impact Factor
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: Objectives: to describe the efficacy and safety of adalimumab (ADA) in inducing clinical remission and reducing inflammation of intestinal mucosa in children with Crohn´s disease (CD).Methods: we carried out a descriptive, observational study with all patients diagnosed with CD and treated with ADA between January 2007 and March 2013. Disease activity was determined using the Pediatric Crohn´s Disease Activity Index (PCDAI), and the degree of mucosa inflammation by fecal calprotectin (FC).Results: sixteen patients were included. Mean age at diagnosis was 10.6 ± 2.5 years, with a mean age at start of ADA treatment of 12.4 ± 1.8 years, and a median of 1.4 years (IQR 0.5-3) duration from CD diagnosis to start of treatment. Twelve patients were naïve to anti-TNF-a. The PCDAI score at start of ADA treatment was significantly reduced at 12 weeks of follow-up (31.25 IQR 26.8-37.5 vs. 1.2 IQR 0.0-5.0; p = 0.001). Similarly, the FC level decreased at 12 weeks (749 μg/g IQR 514-898 vs. 126 μg/g IQR 67.7-239.2; p = 0.02). Surgery was performed in 4 patients. Adverse events were reported in 4 patients. One patient developed lymphoma at 4 years of ADA treatment in monotherapy.Conclusions: ADA has been shown to be effective in children with moderate-to-severe CD. Treatment benefits should be weighed against side effects. Multicenter longitudinal studies with longer follow-up periods are required to determine the true efficacy and safety of long-term ADA treatment.
    Revista espanola de enfermedades digestivas: organo oficial de la Sociedad Espanola de Patologia Digestiva 12/2014; 105(10):579-584. DOI:10.4321/S1130-01082013001000002 · 1.32 Impact Factor